RxDoctor Payments Data

Daniel Grant, MD

Rheumatology · Rome, GANPI 1114377207

Payments from drug & device makers

$1,975in general payments, 2019–2025

Across 85 payments — averaging $23.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$526
  • Davol Inc.$256
  • AbbVie$209
  • Pfizer$189
  • Johnson & Johnson$175
  • UCB, Inc.$119
  • plus $501 from 13 others

What the payments were for

  • Food & beverage$1,76589%
  • Education$21011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,975 in reported general payments places this provider in the 30th percentile of 177 rheumatology providers in Georgia.

See all rheumatology providers in Georgia

Medicare billing

Part B allowed, 2024
$132,980
Medicare patients
544
Services billed
4,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab92$662,930
Enbrel SureclickEtanercept51$379,903
XeljanzTofacitinib Citrate24$135,886
Cosentyx (2 Syringes)Secukinumab13$96,808
Taltz AutoinjectorIxekizumab13$85,589
Humira PenAdalimumab12$78,087
ProliaDenosumab43$73,566
Xeljanz XrTofacitinib Citrate11$61,968
ActemraTocilizumab12$29,041
Hydroxychloroquine Sulfate619$24,246
Mycophenolate Mofetil123$14,765
MethotrexateMethotrexate Sodium541$12,784
Leflunomide161$7,888
Prednisone504$3,355
Cevimeline Hcl21$3,089

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$189$135,88624 claims
NovartisCosentyx (2 Syringes)$111$96,80813 claims
AmgenProlia$526$73,56643 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 177 rheumatology providers in Georgia.

Other rheumatology in Rome

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →